TY - JOUR
T1 - The influence of social determinants of health on epilepsy treatment delays in an Arizona Medicaid population
AU - Sirven, Joseph
AU - Sprout, Gregory T.
AU - Speer, Matthew
AU - Simic, Grant
AU - Ems, Derek
AU - Harootunian, Gevork
AU - Reddy, Swapna
N1 - Funding Information: This work was funded by UCB Pharma. GS (UCB Pharma) and DE (UCB Pharma) were involved in study design; analysis and interpretation of data; the writing of this manuscript for publication; and the decision to submit for publication. UCB Pharma had the opportunity to review and comment on the manuscript. Funding Information: This study was made possible by an ongoing partnership between Arizona State University's Center for Health Information & Research (CHiR) and the Arizona Health Care Cost Containment System (AHCCCS) and the Arizona Medical Board. Special thanks to George Runger, CHiR Director, for his cooperation, and to Varnika Angampally for her valuable technical support. The authors acknowledge Kathleen Richards, PhD (UCB Pharma, Smyrna, GA, USA) for publication coordination. This study was approved by the Institutional Review Board (IRB) of Arizona State University, and the protocols used in this study comply with all local, state, and federal regulations. The IRB granted a Waiver of Informed Consent and approved a Request for HIPAA Waiver of Authorization as the project team would only receive de-identified data sets from the Arizona State University Center for Health Information & Research (CHiR). The de-identified data sets can made be available; however, due to privacy and security requirements and the proprietary nature of the data in CHiR's repository, CHiR cannot make any of its identifiable data sets openly available. Publisher Copyright: © 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Objective: The purpose of this study was to better understand the role of social determinants of health (SDoH) in both treatment delays and treatment gaps for individuals with epilepsy (IWE) enrolled in Arizona's Medicaid program using predictive models at the population and individual levels. Methods: In this retrospective cohort study, two statistical regression models were developed using Arizona Medicaid medical and pharmacy claims records from 2015-2019 and selected census tract-level SDoH data. Three treatment outcomes were defined: timely treatment (treated within thirty days); delayed treatment (treated after thirty days); and untreated. For the first model, least squares regression was used to regress the epilepsy treatment delays on selected SDoH factors at the population-level. For the second model, multinomial logistic regression was used to estimate associations between epilepsy treatment delays and individual-level sociodemographic factors. Results: Of the 5965 IWE identified with a new epilepsy diagnosis during the study period, 43.1% were treated with a mean delay of 180 days. Among the treated population, 42% received timely treatment. A treatment gap of at least 40.6% and potentially up to 56.9% was calculated. Individuals with epilepsy diagnosed in an inpatient setting or in emergency departments were more likely to be treated and receive timely treatment than those diagnosed in an office or clinic setting. Individuals with epilepsy diagnosed in “other” settings were more likely to go untreated or receive delayed treatment than a patient diagnosed in an office or clinic. Compared to IWE aged 31–50 years, IWE aged 0–30 years were more likely to receive timely treatment, IWE aged 51–64 years were more likely to receive delayed treatment, and IWE aged 65 years or older were more likely to go untreated. Widowed IWE were more likely to go untreated relative to single patients. Individuals with epilepsy experiencing homelessness were also more likely to go untreated. Unemployed IWE were more likely to go untreated or receive delayed treatment. Native American IWE were more likely to go untreated compared to White patients. Conclusions: Treatment gaps and treatment delays are experienced by IWE in the Arizona Medicaid population. The SDoH factors predicted to impact treatment delays include care setting, age, race, marital status, homelessness, and employment.
AB - Objective: The purpose of this study was to better understand the role of social determinants of health (SDoH) in both treatment delays and treatment gaps for individuals with epilepsy (IWE) enrolled in Arizona's Medicaid program using predictive models at the population and individual levels. Methods: In this retrospective cohort study, two statistical regression models were developed using Arizona Medicaid medical and pharmacy claims records from 2015-2019 and selected census tract-level SDoH data. Three treatment outcomes were defined: timely treatment (treated within thirty days); delayed treatment (treated after thirty days); and untreated. For the first model, least squares regression was used to regress the epilepsy treatment delays on selected SDoH factors at the population-level. For the second model, multinomial logistic regression was used to estimate associations between epilepsy treatment delays and individual-level sociodemographic factors. Results: Of the 5965 IWE identified with a new epilepsy diagnosis during the study period, 43.1% were treated with a mean delay of 180 days. Among the treated population, 42% received timely treatment. A treatment gap of at least 40.6% and potentially up to 56.9% was calculated. Individuals with epilepsy diagnosed in an inpatient setting or in emergency departments were more likely to be treated and receive timely treatment than those diagnosed in an office or clinic setting. Individuals with epilepsy diagnosed in “other” settings were more likely to go untreated or receive delayed treatment than a patient diagnosed in an office or clinic. Compared to IWE aged 31–50 years, IWE aged 0–30 years were more likely to receive timely treatment, IWE aged 51–64 years were more likely to receive delayed treatment, and IWE aged 65 years or older were more likely to go untreated. Widowed IWE were more likely to go untreated relative to single patients. Individuals with epilepsy experiencing homelessness were also more likely to go untreated. Unemployed IWE were more likely to go untreated or receive delayed treatment. Native American IWE were more likely to go untreated compared to White patients. Conclusions: Treatment gaps and treatment delays are experienced by IWE in the Arizona Medicaid population. The SDoH factors predicted to impact treatment delays include care setting, age, race, marital status, homelessness, and employment.
KW - Medicaid
KW - Newly diagnosed epilepsy
KW - Population health
KW - Social determinants of health
KW - Treatment delays
KW - Treatment gaps
UR - http://www.scopus.com/inward/record.url?scp=85121106288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121106288&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2021.108473
DO - 10.1016/j.yebeh.2021.108473
M3 - Article
C2 - 34920347
SN - 1525-5050
VL - 126
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 108473
ER -